<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04891666</url>
  </required_header>
  <id_info>
    <org_study_id>NZ-GHSG-2020-02</org_study_id>
    <nct_id>NCT04891666</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate the Efficacy and Safety of Lactobacillus Plantarum DSM 33464 on Blood Lead Levels in Children</brief_title>
  <official_title>A Clinical Trial to Evaluate the Efficacy and Safety of Lactobacillus Plantarum DSM 33464 (SmartGuard®) on Blood Lead Levels in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novozymes A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baoding Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Clinical Service Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Novozymes A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a parallel, randomized, double-blind, placebo controlled clinical trial will&#xD;
      evaluate the effect of Lactobacillus plantarum DSM 33464 on reduction of Blood lead levels&#xD;
      and general well-being of children.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of blood lead levels</measure>
    <time_frame>24 weeks</time_frame>
    <description>Difference in reduction of blood lead level between the experimental group and the placebo group at week 24 compared with baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of blood lead levels</measure>
    <time_frame>4 and 12 weeks</time_frame>
    <description>Compared with the baseline, the difference between the reduction of the blood lead level in the experimental group and the placebo group at the 4th and 12th week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of urine lead levels</measure>
    <time_frame>4, 12 and 24 weeks</time_frame>
    <description>Compared with baseline, the difference between the reduction of urine lead levels in the experimental group and the placebo group at the 4th, 12th, and 24th week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of common trace elements-Ca,Zn,Cu,Mg,Fe in the blood</measure>
    <time_frame>4, 12 and 24 weeks</time_frame>
    <description>Compared with baseline, the difference between the improvement of common trace elements Ca,Zn,Cu,Mg,Fe in the blood of the experimental group and the placebo group at the 4th, 12th and 24th week</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Elevated Blood Lead Levels</condition>
  <arm_group>
    <arm_group_label>Lactobacillus plantarum DSM 33464</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 sachet of Lactobacillus plantarum DSM 33464 (2 g) and 1 sachet of supplement YingKangWei per day for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 sachet of placebo (2 g) and 1 sachet of supplement YingKangWei per day for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus plantarum DSM 33464</intervention_name>
    <description>1 sachet SmartGuard® per day for 24 weeks</description>
    <arm_group_label>Lactobacillus plantarum DSM 33464</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>SmartGuard®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The subjects who meet all of the following selection criteria can participate in this&#xD;
        study:&#xD;
&#xD;
          1. Children age 3-12 years&#xD;
&#xD;
          2. BLL 50-199 µg/L&#xD;
&#xD;
          3. Subjects, their parents or legal guardians are able and willing to comply with&#xD;
             research guidance&#xD;
&#xD;
          4. Subject's parents or legal guardians sign written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects who meet any of the following exclusion criteria may not participate in this&#xD;
        study:&#xD;
&#xD;
          1. Diagnosed with nervous system diseases, genetic and metabolic diseases, endocrine&#xD;
             diseases, lung diseases, severe or unstable cardiovascular diseases, clinically&#xD;
             significant kidney or liver diseases, blood system diseases, any other clinically&#xD;
             significant diseases and Other investigators judge that the participation of subjects&#xD;
             in the study will increase the risk of the subjects' diseases;&#xD;
&#xD;
          2. History of infection or organ transplantation of human immunodeficiency virus or other&#xD;
             acquired congenital immunodeficiency diseases;&#xD;
&#xD;
          3. Take probiotic products in the last two weeks&#xD;
&#xD;
          4. Known or suspected sensitivity or allergy to food or any constituents tested in the&#xD;
             trial&#xD;
&#xD;
          5. Participation in another clinical trial or food study 4 weeks prior and during the&#xD;
             trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wenqian Gu</last_name>
    <phone>+4530770423</phone>
    <email>wqg@novozymes.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Baoding children's hospital</name>
      <address>
        <city>Baoding</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jingxia Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Children's Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100045</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimin Liang, Master</last_name>
      <phone>13370116099</phone>
      <email>liang-aimin@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Wenjing Ji</last_name>
      <phone>18610566385</phone>
      <email>jwjee@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 13, 2021</study_first_submitted>
  <study_first_submitted_qc>May 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

